UBS Group
REVBW icon

UBS Group’s Revelation Biosciences Warrant REVBW Stock Holding History

UBS Group’s Portfolio REVBW Stock Details REVBW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28 Buy
3,532
+3,000
+564% +$31 ﹤0.01% 10242
2026
Q1 		$4 Buy
+532
New +$5 ﹤0.01% 10364
2025
Q4 		– Sell
-1,133
Closed -$12 – 11063
2025
Q3 		$12 Sell
1,133
-167
-13% -$2 ﹤0.01% 10174
2025
Q2 		$16 Buy
1,300
+1,028
+378% +$12 ﹤0.01% 10133
2025
Q1 		$3 Sell
272
-2,240
-89% -$34 ﹤0.01% 10150
2024
Q4 		$18 Sell
2,512
-156
-6% -$2 ﹤0.01% 9780
2024
Q3 		$40 Sell
2,668
-2,047
-43% -$29 ﹤0.01% 9255
2024
Q2 		$94 Buy
+4,715
New +$77 ﹤0.01% 9172
2023
Q4 		– Sell
-78,000
Closed -$1.33K – 9790
2023
Q3 		$1.33K Buy
+78,000
New +$1.29K ﹤0.01% 7985
2023
Q2 		– Sell
-6,089
Closed -$97 – 9515
2023
Q1 		$97 Buy
+6,089
New +$153 ﹤0.01% 9250
2022
Q4 		– Sell
-5,124
Closed – – 11065
2022
Q3 		$0 Sell
5,124
-13,631
-73% -$1.11K ﹤0.01% 10824
2022
Q2 		$2K Buy
18,755
+12,336
+192% +$1.03K ﹤0.01% 9606
2022
Q1 		$1K Sell
6,419
-421
-6% -$108 ﹤0.01% 9909
2021
Q4 		$5K Buy
+6,840
New +$4.19K ﹤0.01% 9412
2021
Q3 		– Sell
-1,015
Closed -$1K – 9989
2021
Q2 		$1K Sell
1,015
-302
-23% -$180 ﹤0.01% 9181
2021
Q1 		$1K Buy
+1,317
New +$1.23K ﹤0.01% 8791

Other funds holding REVBW

LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
PVI
Pine Valley Investments Marlton, New Jersey $2.53B AUM 36.18% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
SIA
Soltis Investment Advisors St. George, Utah $1.8B AUM 27.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS Group's REVBW Position: Q2 2026 in Review

UBS Group increased its Revelation Biosciences Warrant (REVBW) stake by 564% in Q2 2026, buying an estimated $31 and bringing the position to 3,532 shares worth $28. The position accounts for ﹤0.01% of the portfolio, ranked #10242.

UBS Group first reported a position in REVBW in Q1 2021 and has held it in 16 quarters since. The position peaked at $5K in Q4 2021. 13 funds tracked by Wall St. Rank hold REVBW as of Q2 2026.

  • UBS Group held 3,532 shares of Revelation Biosciences Warrant worth $28 as of Q2 2026.
  • UBS Group bought 3,000 Revelation Biosciences Warrant shares in Q2 2026, an estimated $31.
  • Revelation Biosciences Warrant made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10242 holding.
  • UBS Group first reported a position in Revelation Biosciences Warrant in Q1 2021 and has held it in 16 quarters since.
  • UBS Group's Revelation Biosciences Warrant position peaked at $5K in Q4 2021.
  • 13 funds tracked by Wall St. Rank held Revelation Biosciences Warrant as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.